AIP Form 4: Director Raza Trades $200K in Stock via Pre-Set Plan
Rhea-AI Filing Summary
Arteris, Inc. (AIP) – Form 4 Insider Transaction
Director S. Atiq Raza, acting through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold 19,809 shares of Arteris common stock on 27 June 2025 under a pre-arranged Rule 10b5-1 trading plan adopted on 6 June 2024. The weighted-average sale price was $10.02 per share (individual trade prices ranged from $10.00 to $10.10).
Following the transaction, the trust continues to hold 683,798 shares, leaving Mr. Raza with a substantial ownership position. The filing states that the trade was reported on 1 July 2025 and was executed indirectly through the trust.
- Form type: SEC Form 4
- Insider role: Director
- Nature of trade: Open-market sale (code “S”)
- Approximate transaction value: $199,000
The relatively small percentage of shares sold (≈2.8 % of the insider’s reported holdings) and the existence of a 10b5-1 plan mitigate potential negative signalling, yet investors often monitor insider sales for sentiment clues.
Positive
- Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic trading and signalling adherence to governance best practices.
- Director still holds 683,798 shares, preserving substantial insider alignment with shareholders.
Negative
- Insider sale of 19,809 shares may be interpreted by some investors as a cautious sentiment signal, even if modest in size.
Insights
TL;DR: Modest 20k-share 10b5-1 sale; ownership still high, neutral signal.
The disposition represents about 2.8 % of Mr. Raza’s 703,600 pre-sale shares, raising roughly $0.2 million. Because the transaction was executed under a previously adopted 10b5-1 plan, it is less likely to indicate a short-term view on fundamentals. Post-sale ownership of 683,798 shares remains material, aligning director incentives with shareholders. From a valuation standpoint, the sale is immaterial to market cap and does not alter free-float dynamics meaningfully. I view the disclosure as neutral for the equity.
TL;DR: Pre-planned sale limits governance concern; monitor future activity.
Insider sales can raise red flags, but the affirmative 10b5-1 disclosure satisfies best-practice transparency standards. The weighted-average pricing disclosure and willingness to provide granular trade data on request further support governance quality. The director retains a sizeable stake, maintaining alignment. Unless a pattern of accelerated selling emerges, the event is not materially negative for shareholder oversight.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 19,809 | $10.0203 | $198K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 6, 2024. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.10 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.
